Navigation

Navigation

Investment Banking

Health Care

The Health Care Group's mission is to provide the highest quality of financial advisory, capital raising, and sales and trading services to health care companies worldwide.

The Health Care Group has extensive experience in financial advisory activities such as mergers, acquisitions, cross-border advisory, spin-offs, divestitures, and corporate sales; underwritings of equity, equity-linked, high-yield, and investment grade securities; as well as commercial banking products.

The group brings unparalleled transaction execution experience with:

  • Significant M&A experience, which includes some of the largest and most innovative transactions
  • Leading equity, debt and high yield capital raising capabilities
  • Strong capabilities and expertise executing cross-border transaction

We have established a proven track record as the premier health care investment bank. Some noteworthy transactions that our Health Care Group has advised on include:

Equity

  • Joint Bookrunner on Express Scripts' $1.6 Billion Follow-on
  • Joint Bookrunner on Mead Johnson's $828 Million IPO
  • Joint Bookrunner on Warner Chilcott's $512 Million Follow-on
  • Joint Bookrunner on EMS's $368 Million Follow-on
  • Joint Bookrunner on Medidata's $101 Million IPO

Debt

  • Joint Bookrunner on Roche's $33.3 Billion bond offering
  • Joint Arranger on Pfizer's $22.5 Billion bridge loan and Joint Bookrunner on Pfizer's $13.5 Billion multi-tranche bond offering
  • Joint Bookrunner on Merck's $4.3 Billion bond offering
  • Administrative Agent and Joint Lead Arranger for Warner Chilcott's $3.2 Billion Senior Credit Facilities
  • Joint Bookrunner on Express Scripts' $2.5 Billion bond offering

M&A

  • Joint Financial Advisor to Express Scripts' $4.7 Billion acquisition of WellPoint's NetRx PBM business
  • Exclusive Financial Advisor to Merck on the sale of its 50% interest in Merial to Sanofi-Aventis for $4.0 Billion
  • Joint Advisor to Warner Chilcott on its acquisition of Procter & Gamble's global pharmaceutical business for $3.1 Billion
  • Lead Financial Advisor to King Pharmaceuticals on its $1.6 Billion acquisition of Alpharma
  • Exclusive Advisor to Nestle in its $39 Billion sale of Alcon to Novartis

Secondary Content

Contact